Anatomic Location Predicts Response Rates: Real World Outcomes With Over 1100 Cycles of Talimogene Laherparepvec...

Area of Science:

• Oncology
• Dermatology
• Viral Oncology

Background:

• Talimogene laherparepvec (TVEC) is an FDA-approved oncolytic virus for unresectable metastatic melanoma.
• Previous studies reported a 39% complete response (CR) rate for TVEC.

Purpose of the Study:

• To investigate the association between the anatomic location of metastatic melanoma and the therapeutic response to TVEC.
• To evaluate real-world outcomes of TVEC treatment in a prospective cohort.

Main Methods:

• Prospective analysis of a single-center melanoma database (December 2015-December 2023).
• Patients categorized by treated anatomic sites (head/neck, lower extremity, torso, upper extremity).
• Statistical analysis using generalized estimating equation models to assess treatment response relative to anatomic sites.

Main Results:

• 173 patients with 190 TVEC treatment plans were analyzed.
• Complete response (CR) observed in 41.6% of patients.
• Head and neck metastases showed the highest CR rate (50.6% within the CR group).

Conclusions:

• TVEC is a well-tolerated and durable treatment for advanced melanoma.
• Anatomic location significantly influences TVEC treatment response.
• Head and neck metastases exhibit superior CR rates, indicating potential for TVEC as a first-line option in select cases.